射血分数保留的心力衰竭:诊断、机制与管理的新概念
本文为叙述性综述,总结射血分数保留的心力衰竭(HFpEF)的病理生理、诊断、分类和管理。HFpEF约占心衰患者一半,诊断和治疗仍具挑战;随着LVEF升高,心脏性住院和死亡比例下降,非心脏共病负担增加;SGLT2抑制剂可减少复合心血管事件(主要由心衰住院减少驱动),RAAS阻滞剂和ARNI减少心衰住院的幅度较小;综合管理包括运动及危险因素和共病治疗。
要点
- HFpEF约占心衰患者一半,诊断需排除其他呼吸困难原因及HFpEF模仿者。
- 随LVEF升高,心脏性住院和死亡比例下降,非心脏共病负担增加。
- SGLT2抑制剂减少复合心血管事件,主要由心衰住院减少驱动。
核心结论
- HFpEF是诊断和治疗挑战,需综合管理包括运动及危险因素和共病治疗。
- 基于表型的分类可能比LVEF分类更利于靶向治疗。
研究设计与样本
- 叙述性综述,总结HFpEF的病理生理、诊断、分类和管理。
主要发现
- HFpEF约占心衰患者一半。
- 随LVEF升高,心脏性住院和死亡比例下降。
- 在HFrEF有效的药物类别在较高LVEF范围效果较差,降低心衰住院风险但不降低心血管或全因死亡。
- SGLT2抑制剂减少复合心血管事件,由心衰住院减少驱动。
- RAAS阻滞剂和ARNI在HFpEF中减少心衰住院的幅度较小。
关键数值与推荐
- 区分HFpEF与其他呼吸困难原因可能需要运动超声心动图、有创血流动力学和HFpEF模仿者检查。
- HF分类依赖LVEF切点,但LVEF为连续变量,切点 arbitrary。
临床怎么用
- 综合管理HFpEF包括运动及治疗危险因素和共病。
- 基于表型的分类可能促进更靶向的治疗方法。
局限性
- 本文为叙述性综述,未报告系统检索范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is estimated that half of all patients with heart failure (HF) have HF with preserved ejection fraction (HFpEF). Yet this form of HF remains a diagnostic and therapeutic challenge. Differentiating HFpEF from other causes of dyspnoea may require advanced diagnostic methods, such as exercise echocardiography, invasive haemodynamics and investigations for 'HFpEF mimickers'. While the classification of HF has relied heavily on cut-points in left ventricular ejection fraction (LVEF), recent evidence points towards a gradual shift in underlying mechanisms, phenotypes and response to therapies as LVEF increases. For example, among patients with HF, the proportion of hospitalisations and deaths due to cardiac causes decreases as LVEF increases. Medication classes that are efficacious in HF with reduced ejection fraction (HFrEF) have been less so at higher LVEF ranges, decreasing the risk of HF hospitalisation but not cardiovascular or all-cause death in HFpEF. These observations reflect the burden of non-cardiac comorbidities as LVEF increases and highlight the complex pathophysiological mechanisms, both cardiac and non-cardiac, underpinning HFpEF. Treatment with sodium-glucose cotransporter 2 inhibitors reduces the risk of composite cardiovascular events, driven by a reduction in HF hospitalisations; renin-angiotensin-aldosterone blockers and angiotensin-neprilysin inhibitors result in smaller reductions in HF hospitalisations among patients with HFpEF. Comprehensive management of HFpEF includes exercise as well as treatment of risk factors and comorbidities. Classification based on phenotypes may facilitate a more targeted approach to treatment than LVEF categorisation, which sets arbitrary cut-points when LVEF is a continuum. This narrative review summarises the pathophysiology, diagnosis, classification and management of patients with HFpEF.
引用
- Gevaert, Kataria, Zannad, et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022. PMID: 35022210. doi:10.1136/heartjnl-2021-319605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。